Exosomal miR‐663b targets Ets2‐repressor factor to promote proliferation and the epithelial–mesenchymal transition of bladder cancer cells. (6th January 2020)

• Record Type: Journal Article
• Authors: Yin, Xinbao; Zheng, Xueping; Liu, Ming; Wang, Dong; Sun, Hui; Qiu, Yue; Chen, Jun; Shi, Benkang
• Is Part Of: Cell biology international. Volume 44:Number 4(2020)
• Page Start: 958
• Page End: 965
• Publication Date: 2020-01-06
• Subjects: bladder cancer -- cell proliferation -- epithelial–mesenchymal transition -- Ets2‐repressor factor -- exosomes -- microRNA‐663b; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.11292
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: Exosomes circulating in biological fluids have the potential to be utilized as cancer biomarkers and are associated with cancer progression and metastasis. MicroRNA (miR)‐663b has been found to be elevated in plasma from patients with bladder cancer (BC). However, the functional role of exosomal miR‐663b in BC processes remains unknown. Here, we isolated exosomes from plasma and found that the miR‐663b level was elevated in exosomes from plasma of patients with BC compared with healthy controls. Exosomal miR‐663b from BC cells promoted cell proliferation and epithelial–mesenchymal transition. Moreover, exosomal miR‐663b targeted Ets2‐repressor factor and acted as a tumor promoter in BC cells. Taken together, our findings suggested that exosomal miR‐663b is a promising potential biomarker and target for clinical detection and therapy in BC.